



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:  
Jeffrey L. Browning et al.

Examiner: Not Assigned

Group Art Unit: 1642

Serial No.: 10/003,211

Filing Date: October 31, 2001

For: Soluble Lymphotoxin-Beta Receptors as Therapeutic Agents for  
Treatment of Systemic Lupus Erythematosus (as amended)

COPY OF PAPERS  
ORIGINAL FILED

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on:

July 3, 2002  
Date

*[Signature]*

Jacqueline L. Marlier

COMMUNICATION TO CORRECT ERROR IN FILING RECEIPT

Box Missing Parts  
Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Upon receipt of the Official Filing Receipt for the above-referenced application, a copy of which is attached, the applicant noticed that the PCT priority application number is incorrect.

The PCT application reads:

PCT/US97/19435

should read:

PCT/US97/19436

If any fee is required, authorization is hereby given to charge Deposit Account  
No. 02-2327.

Respectfully submitted,

Date:

July 3, 2002



Niki D. Cox, Esq.

Reg. No. 42, 446

BIOGEN, INC.

14 Cambridge Center

Cambridge, MA 02142

(617) 679-2079 (Direct)

(617) 679-2838 (Facsimile)

10893

COPY OF PAPERS  
ORIGINALLY FILED

## UNITED STATES PATENT AND TRADEMARK OFFICE

JUL 09 2002

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/003,211	10/31/2001	1642	740	A013 US CON	7	8	1


Niki D. Cox, Esq.  
BIOGEN, INC.  
14 Cambridge Center  
Cambridge, MA 02142

JAN 10 2002

NDC

CONFIRMATION NO. 6970

## FILING RECEIPT



\*OC000000007268484\*

Date Mailed: 01/04/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Jeffrey L. Browning, Brookline, MA;  
Paula S. Hochman, Newton, MA;  
Paul D. Rennert, Millis, MA;  
Fabienne MacKay, Vaucluse, AUSTRALIA;

## Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 09/299,139 04/23/1999  
WHICH CLAIMS BENEFIT OF 60/029,060 10/25/1996

## Foreign Applications

PCT/US97/19435 10/24/1997

PCT/US97/19436

If Required, Foreign Filing License Granted 01/04/2002

Projected Publication Date: To Be Determined - pending completion of Corrected Papers

Non-Publication Request: No

Early Publication Request: No

## Title

Soluble lymphotoxin beta receptor and anti-lymphotoxin receptor and ligand antibodies as



therapeutic agents for treatment

Preliminary Class

514

COPY OF PAPERS  
ORIGINAL FILED

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**


The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



Docket No. A013USCON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:  
Jeffrey L. Browning et al.

Examiner: Not Assigned

Group Art Unit: 1642

Serial No.: 10/003,211

Filing Date: October 31, 2001

For: Soluble Lymphotoxin-Beta Receptors as Therapeutic Agents for Treatment of Systemic Lupus Erythematosus (as amended)

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on:

July 3, 2002  
Date

Jacqueline L. Marlier

RESPONSE TO NOTICE TO FILE CORRECTED  
APPLICATION PAPERS

In response to the Notice to File Corrected Application Papers of a Nonprovisional Application mailed January 4, 2002, Applicant hereby submits copy of notice and substitute drawings in compliance with 37 CFR 1.84.

No fee is deemed necessary in connection with the filing of this Response. However, in an abundance of caution, if any fee is required, authorization is hereby given to charge Deposit Account No. 02-2327.


Respectfully submitted,

Date:

July 3, 2002

Niki D. Cox, Esq.  
Reg. No. 42, 446  
BIOGEN, INC.  
14 Cambridge Center  
Cambridge, MA 02142  
(617) 679-2079 (Direct)  
(617) 679-2838 (Facsimile)

COPY OF PAPERS  
ORIGINALLY FILED



COPY OF PAPERS  
ORIGINALLY FILED

PTO/SB/17 (10-01)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$ 1,440

## Complete if Known

Application Number	10/003,211
Filing Date	10/31/2001
First Named Inventor	Browning, Jeffrey
Examiner Name	TBD
Group Art Unit	1642
Attorney Docket No.	A013 US CON

## METHOD OF PAYMENT

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number 02-2327  
Deposit Account Name

- ☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17  
☐ Applicant claims small entity status. See 37 CFR 1.27

2. ☐ Payment Enclosed:

☐ Check ☐ Credit card ☐ Money Order ☐ Other

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
101 740	201 370	Utility filing fee	
106 330	206 165	Design filing fee	
107 510	207 255	Plant filing fee	
108 740	208 370	Reissue filing fee	
114 160	214 80	Provisional filing fee	

SUBTOTAL (1) (\$ 0

### 2. EXTRA CLAIM FEES

Total Claims  -20\*\* =  X  = 0  
Independent Claims  - 3\*\* =  X  = 0  
Multiple Dependent  = 0

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
103 18	203 9	Claims in excess of 20
102 84	202 42	Independent claims in excess of 3
104 280	204 140	Multiple dependent claim, if not paid
109 84	209 42	** Reissue independent claims over original patent
110 18	210 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$ 0

\*\*or number previously paid, if greater; For Reissues, see above

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
105 130	205 65	Surcharge - late filing fee or oath	
127 50	227 25	Surcharge - late provisional filing fee or cover sheet	
139 130	139 130	Non-English specification	
147 2,520	147 2,520	For filing a request for <i>ex parte</i> reexamination	
112 920*	112 920*	Requesting publication of SIR prior to Examiner action	
113 1,840*	113 1,840*	Requesting publication of SIR after Examiner action	
115 110	215 55	Extension for reply within first month	
116 400	216 200	Extension for reply within second month	
117 920	217 460	Extension for reply within third month	
118 1,440	218 720	Extension for reply within fourth month	1,440
128 1,960	228 980	Extension for reply within fifth month	
119 320	219 160	Notice of Appeal	
120 320	220 160	Filing a brief in support of an appeal	
121 280	221 140	Request for oral hearing	
138 1,510	138 1,510	Petition to institute a public use proceeding	
140 110	240 55	Petition to revive - unavoidable	
141 1,280	241 640	Petition to revive - unintentional	
142 1,280	242 640	Utility issue fee (or reissue)	
143 460	243 230	Design issue fee	
144 620	244 310	Plant issue fee	
122 130	122 130	Petitions to the Commissioner	
123 50	123 50	Processing fee under 37 CFR 1.17(q)	
126 180	126 180	Submission of Information Disclosure Stmt	
581 40	581 40	Recording each patent assignment per property (times number of properties)	
146 740	246 370	Filing a submission after final rejection (37 CFR § 1.129(a))	
149 740	249 370	For each additional invention to be examined (37 CFR § 1.129(b))	
179 740	279 370	Request for Continued Examination (RCE)	
169 900	169 900	Request for expedited examination of a design application	

Other fee (specify)

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$ 1,440

## SUBMITTED BY

Complete (if applicable)

Name (Print/Type)	Niki D. Cox	Registration No. (Attorney/Agent)	42,446	Telephone	(617) 679-2079
Signature	<i>Niki D. Cox</i>	Date	July 3, 2002		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

# 4



## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

**BOX: Missing Parts**

Assistant Commissioner for Patents  
Washington, D.C. 20231

on July 3, 2002  
Date

Signature

Jacqueline L. Marlier

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

1. Transmittal Form (1 pg.);
2. Fee Transmittal Form (1 pg.);
3. Response to Notice to File Corrected Application Papers (1 pg.);
4. Communication to Correct Error in Filing Receipt (2 pgs.);
5. Copy of Notice to File Corrected Application Papers (1 pg.);
6. Copy of marked-up Filing Receipt (2 pgs.);
7. 10 Sheets of Substitute Drawings;
8. Petition for a 4-Month Extension of Time (1 pg.);
9. Return Receipt Postcard

COPY OF PAPERS  
ORIGINALY FILED